AudioCure Pharma
Pharmaceutical company with a focus on hearing impairments.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* | N/A | Late VC | |
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (50 %) | 25 % | - | (52 %) | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 21 % | 12 % | (29 %) | (134 %) | (290 %) | (456 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
AudioCure Pharma is a pioneering biopharmaceutical company focused on developing novel drug treatments for hearing disorders, particularly acute hearing loss and acute tinnitus. With over 360 million people globally affected by hearing loss, the company addresses a significant unmet medical need. AudioCure's lead candidate, AC102, is a groundbreaking molecule designed to protect and restore inner ear cells, potentially becoming the first causative therapy for these conditions. The company operates in the healthcare and pharmaceutical market, primarily serving patients suffering from sensorineural hearing loss disorders. AudioCure's business model revolves around the research, development, and eventual commercialization of its drug candidates. Revenue is anticipated through the successful approval and sale of these innovative treatments.
Keywords: biopharmaceutical, hearing loss, tinnitus, AC102, inner ear cells, sensorineural, drug development, healthcare, pharmaceutical, unmet medical need.